Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
Body unavailable. Use the original source.
Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.